Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
EDICT (endothelial dystrophy-iris hypoplasia-congenital cataract-stromal thinning) syndrome is a very rare eye disorder representing a constellation of autosomal dominantly inherited ocular findings, including early-onset or congenital cataracts, corneal stromal thinning, early-onset keratoconus, corneal endothelial dystrophy, and iris hypoplasia.
Features include always present findings: Astigmatism, Keratoconus, and Anterior polar cataract. 7 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 3 | Keratoconus, Anterior polar cataract, Visual impairment |
Age of onset: adolescence, childhood.
MIR184 encodes microRNA 184. Highest expression in Adipose Subcutaneous (0.0 TPM) and Adipose Visceral Omentum (0.0 TPM).
EDICT syndrome is associated with mutations in the MIR184 gene on chromosome 15.
MIR184 is classified as a druggable target with score 0.0.
Genetic testing for MIR184 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for EDICT syndrome has been reported in the published literature.
Phenotype severity distribution: 3 always present features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for EDICT syndrome.
7 publications have been identified in PubMed for EDICT syndrome. Research spans Epidemiology / Natural History (43%), Review / Meta-Analysis (29%), and Diagnostic / Biomarker (14%).
Vieira IV (2026). [PMID: 41212223](https://pubmed.ncbi.nlm.nih.gov/41212223/). *Graefes Arch Clin Exp Ophthalmol*. [Review / Meta-Analysis]
Alqasimi NA (2025). [PMID: 40008187](https://pubmed.ncbi.nlm.nih.gov/40008187/). *Front Ophthalmol (Lausanne)*. [Epidemiology / Natural History]
Ezinne NE (2025). [PMID: 40135077](https://pubmed.ncbi.nlm.nih.gov/40135077/). *Health Sci Rep*. [Epidemiology / Natural History]
Al-Dwairi R (2024). [PMID: 39768304](https://pubmed.ncbi.nlm.nih.gov/39768304/). *Life (Basel)*. [Diagnostic / Biomarker]
Bardoloi P (2024). [PMID: 37921523](https://pubmed.ncbi.nlm.nih.gov/37921523/). *Cornea*. [Clinical Trial Publication]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 11:11 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about EDICT syndrome
Goel H (2024). [PMID: 39457367](https://pubmed.ncbi.nlm.nih.gov/39457367/). *Genes (Basel)*. [Review / Meta-Analysis]